BRIEF published on 08/08/2025 at 02:20, 9 months 5 days ago CureVac Settles Patent Dispute with Pfizer/BioNTech MRNA Technology CureVac Pfizer/BioNTech Patent Resolution Vaccine Royalties
PRESS RELEASE published on 08/08/2025 at 02:15, 9 months 5 days ago CureVac Announces Resolution of Patent Litigation with Pfizer/BioNTech CureVac resolves patent litigation with Pfizer/BioNTech related to mRNA-based COVID-19 vaccines, receiving $790 million and non-exclusive license agreements BioNTech MRNA Technology CureVac Patent Litigation Pfizer
BRIEF published on 06/24/2025 at 22:14, 10 months 18 days ago CureVac publie les résultats de son assemblée générale annuelle CureVac Nominations Au Conseil D'administration Commissaires Aux Comptes Technologie De L'ARNm Assemblée Annuelle
BRIEF published on 06/24/2025 at 22:14, 10 months 18 days ago CureVac Reports Outcomes of Annual General Meeting MRNA Technology Annual Meeting Board Appointments Auditors CureVac
PRESS RELEASE published on 06/24/2025 at 22:09, 10 months 18 days ago CureVac Announces Voting Results of General Meeting CureVac announces voting results of Annual General Meeting, including new Management Board and Supervisory Board appointments. KPMG reappointed as external auditors Annual General Meeting Appointments Voting Results KPMG CureVac
BRIEF published on 05/20/2025 at 13:05, 11 months 23 days ago CureVac Reports Q1 2025 Financials and Business Developments Financial Results Revenue Patents Oncology Pipeline R&D Developments
BRIEF published on 05/20/2025 at 13:05, 11 months 23 days ago CureVac publie ses résultats financiers et ses développements commerciaux pour le premier trimestre 2025 Résultats Financiers Brevets Revenu Pipeline En Oncologie Développements En R&D
PRESS RELEASE published on 05/20/2025 at 13:00, 11 months 23 days ago CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates CureVac announces financial results for Q1 2025 and updates on lung cancer and glioblastoma trials, urinary tract infection vaccine, and mRNA patents. Cash position strong at €438.3 million Financial Results Oncology Pipeline CureVac Q1 2025 MRNA Patents
BRIEF published on 05/15/2025 at 22:15, 11 months 28 days ago CureVac Gains Favorable Patent Decision Against BioNTech BioNTech MRNA Technology CureVac Patent Litigation European Patent Office
BRIEF published on 05/15/2025 at 22:15, 11 months 28 days ago CureVac obtient une décision favorable en matière de brevets contre BioNTech BioNTech CureVac Technologie De L'ARNm Office Européen Des Brevets Litiges En Matière De Brevets
Published on 05/13/2026 at 00:00, 3 hours 49 minutes ago Onco-Innovations Announces Initiation of Research Collaboration within PROmAI
Published on 05/12/2026 at 23:35, 4 hours 14 minutes ago Infield Minerals Closes $1.25 Million Financing
Published on 05/12/2026 at 21:55, 5 hours 54 minutes ago UraniumX Discovery Corp Announces Option Agreement with Gold'n Futures
Published on 05/12/2026 at 21:42, 6 hours 7 minutes ago Kidoz Inc. to Present at Planet MicroCap Las Vegas 2026
Published on 05/12/2026 at 23:47, 4 hours 1 minute ago Nebius welcomes Clarifai’s core team and licenses inference IP to strengthen Nebius Token Factory
Published on 05/12/2026 at 22:25, 5 hours 23 minutes ago Evotec SE Successfully Placed €116.1 Million Convertible Bonds
Published on 05/12/2026 at 20:21, 7 hours 27 minutes ago Nebius breaks ground on gigawatt-scale AI factory in Independence, Missouri
Published on 05/12/2026 at 19:35, 8 hours 13 minutes ago AUSTRIACARD HOLDINGS AG: Q1 2026 Financial Results
Published on 05/12/2026 at 19:35, 8 hours 14 minutes ago 2026 Annual General Meeting: Strong vote by shareholders in favour of continuity in leadership and strategy
Published on 05/12/2026 at 18:15, 9 hours 34 minutes ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 30/04/2026
Published on 05/12/2026 at 18:15, 9 hours 34 minutes ago AXA: Information relating to the number of voting rights and shares making up the share capital on 30/04/2026
Published on 05/12/2026 at 18:10, 9 hours 39 minutes ago imerys-12-05-2026-communiqué-compte-rendu-de-l-assemblée-générale-ordinaire-du-12-mai-2026
Published on 05/12/2026 at 18:10, 9 hours 39 minutes ago imerys-12-05-2026-press-release-summary-of-the-ordinary-shareholders-general-meeting-12-may-2026
Published on 05/12/2026 at 17:50, 9 hours 59 minutes ago Damartex fait évoluer sa gouvernance et engage une réflexion stratégique autour de ses activités
